‘A very, very bad look’ for remdesivir
Jon Cohen, Kai Kupferschmidt
Abstract
FDA and Europe anointed it as a key therapy just after a major study found it has little value.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMedicineInternal medicineInfectious disease (medical specialty)DiseasePharmacological Receptor Mechanisms and EffectsCOVID-19 Clinical Research StudiesCancer, Stress, Anesthesia, and Immune Response